ABvac 42

Drug Profile

ABvac 42

Alternative Names: ABvac42

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Araclon Biotech
  • Class Alzheimer vaccines; Nootropics; Peptide vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 07 Oct 2016 ABvac 42 is still in phase I trials for Alzheimer's disease in Spain (Araclon Biotech pipeline, October 2016)
  • 07 Oct 2016 Araclon Biotech plans a phase II trial for Alzheimer's disease in Spain (Araclon Biotech pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alzheimer's-disease in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top